--- title: "Rozanolixizumab (Rystiggo): The Subcutaneous FcRn Blocker That Reached Both Myasthenia Serotypes First (July 25, 2026) | PepTracker Pro Blog" description: "Two days after efgartigimod and one after nipocalimab, meet the third FcRn blocker. Rozanolixizumab uses the same trick - stop the receptor that recycles your antibodies - but delivered under the skin, in cycles, and it was the first drug approved to cover both the AChR- and MuSK-antibody myasthenia serotypes. It's also an honest lesson in the mechanism's limits: it failed in CIDP." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "Article", "headline": "Rozanolixizumab (Rystiggo): The Subcutaneous FcRn Blocker That Reached Both Myasthenia Serotypes First (July 25, 2026)", "description": "Two days after efgartigimod and one after nipocalimab, meet the third FcRn blocker. Rozanolixizumab uses the same trick - stop the receptor that recycles your antibodies - but delivered under the skin, in cycles, and it was the first drug approved to cover both the AChR- and MuSK-antibody myasthenia serotypes. It's also an honest lesson in the mechanism's limits: it failed in CIDP.", "datePublished": "2026-07-25", "dateModified": "2026-07-25", "author": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "publisher": { "@type": "Organization", "name": "PepTracker Pro", "logo": { "@type": "ImageObject", "url": "https://peptrackerpro.com/favicon.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://peptrackerpro.com/blog/rozanolixizumab-rystiggo-ucb7665-fcrn-blocker-subcutaneous-igg4-myasthenia-gravis-musk-cidp-mycaring-july-25-2026" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://peptrackerpro.com/blog" }, { "@type": "ListItem", "position": 3, "name": "Rozanolixizumab (Rystiggo): The Subcutaneous FcRn Blocker That Reached Both Myasthenia Serotypes First (July 25, 2026)", "item": "https://peptrackerpro.com/blog/rozanolixizumab-rystiggo-ucb7665-fcrn-blocker-subcutaneous-igg4-myasthenia-gravis-musk-cidp-mycaring-july-25-2026" } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Blog](/blog)/ Rozanolixizumab (Rystiggo): The Subcutaneous FcRn Blocker That Reached Both Myasthenia Serotypes First (July 25, 2026) Research & Compounds Research & Compounds # Rozanolixizumab (Rystiggo): The Subcutaneous FcRn Blocker That Reached Both Myasthenia Serotypes First (July 25, 2026) PepTracker Pro Research Team July 25, 2026 8 min read ## Table of Contents - [The same trick, now under the skin](#section-0) - [A full IgG4 antibody, given as a subcutaneous cycle](#section-1) - [First to cover both myasthenia serotypes](#section-2) - [MycarinG: the pivotal evidence](#section-3) - [The honest part: it failed in CIDP](#section-4) - [Where it's headed next](#section-5) - [How it fits the FcRn class - and one important caveat](#section-6) ## The same trick, now under the skin Over the last two days this series introduced the two most prominent FcRn blockers - efgartigimod (Vyvgart) and nipocalimab (Imaavy) - both built on the same idea: the neonatal Fc receptor, FcRn, is the salvage receptor that grabs your antibodies inside cells and ferries them back into the blood, giving IgG its long life. Block FcRn and unrescued IgG, including the pathogenic autoantibodies that cause diseases like myasthenia gravis, is routed to the lysosome and destroyed instead. Rozanolixizumab (brand name Rystiggo, development code UCB7665, from UCB) is the third member of that class to reach the market. It hits the same target and produces the same result - total IgG falls by roughly 70-80% while IgM, IgA, complement, and albumin are left essentially untouched - but it arrives there with a different molecule and a different delivery style. ## A full IgG4 antibody, given as a subcutaneous cycle The three first-generation FcRn blockers are a small case study in antibody engineering. Efgartigimod is an isolated, engineered Fc fragment. Nipocalimab is a full-length, aglycosylated 'effectorless' IgG1. Rozanolixizumab is a humanized, full-length IgG4 monoclonal antibody that binds human FcRn with very high affinity and accelerates the catabolism of circulating IgG. Just as important as the molecule is the route. Where nipocalimab is an intravenous infusion, rozanolixizumab was designed for subcutaneous delivery - a rapid manual push or an on-body infusion device - given as once-weekly infusions in short cycles that are repeated based on how a patient responds. That puts it closer to efgartigimod's cyclic 'reduce and re-treat' rhythm than to a continuous IV maintenance schedule, and it makes rozanolixizumab the class's most portable option. ## First to cover both myasthenia serotypes The headline feature of rozanolixizumab's approval is breadth of serotype coverage. When the FDA cleared Rystiggo on June 27, 2023, it became the first - and at the time only - therapy approved to treat generalized myasthenia gravis in both anti-acetylcholine-receptor (AChR) antibody-positive and anti-muscle-specific-tyrosine-kinase (MuSK) antibody-positive adults. That mattered because MuSK-positive myasthenia is less common and historically harder to treat, and efgartigimod was initially approved only for AChR-positive disease. Rozanolixizumab reached explicit MuSK coverage before either efgartigimod (which later broadened to all serotypes) or nipocalimab (approved in 2025 for AChR- and MuSK-positive patients aged 12 and up). ## MycarinG: the pivotal evidence Approval rested on MycarinG (NCT03971422), a Phase 3, randomized, double-blind, placebo-controlled, adaptive study run across sites in Asia, Europe, and North America. Adults with gMG were randomized to once-weekly subcutaneous rozanolixizumab at 7 mg/kg or 10 mg/kg, or placebo, for six weeks. Both doses produced statistically significant improvements in the MG-ADL daily-living score versus placebo, and a prespecified subgroup analysis confirmed benefit in the MuSK-positive population specifically - one of the cleaner controlled datasets in that hard-to-treat subtype. The pivotal results were published in The Lancet Neurology in 2023, and long-term open-label extensions (MG0004 and MG0007) went on to support the safety and durability of repeated cyclical dosing. ## The honest part: it failed in CIDP Rozanolixizumab is also a useful lesson in the limits of the FcRn mechanism, not just its promise. In chronic inflammatory demyelinating polyneuropathy (CIDP), the Phase 2a CIDP01 study and its open-label extension found the drug well tolerated over as long as ~614 days but without clinically meaningful efficacy, and UCB elected not to advance it to a Phase 3 CIDP program. That is a striking contrast with efgartigimod, which is approved in CIDP - and a reminder that simply lowering IgG does not help every antibody-associated disease equally. Whether the CIDP result reflects the disease, the trial design (a high placebo-stability rate was noted), or the specific molecule is still debated, but as a data point it sharpens the central question of the whole class: which IgG-driven diseases actually respond to draining the antibody pool? ## Where it's headed next Beyond myasthenia gravis, rozanolixizumab is in Phase 3 development for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), an inflammatory demyelinating condition driven by anti-MOG IgG, with studies reading out over 2026-2027. It was also studied earlier in primary immune thrombocytopenia (ITP), and it remains of interest across other IgG-mediated conditions. Regulators outside the U.S. followed the FDA: the European Medicines Agency approved it in January 2024 and the UK MHRA in March 2024. The most common adverse effects - headache, infections, and administration-related reactions - track the class's core trade-off: deliberately lowering IgG raises susceptibility to infection, and new severe headache with fever or neck stiffness warrants prompt evaluation given reports of meningitis-like reactions with FcRn-directed therapies. ## How it fits the FcRn class - and one important caveat Read together, the three first-generation FcRn blockers now map cleanly onto three axes. Format: Fc fragment (efgartigimod) vs aglycosylated IgG1 (nipocalimab) vs full IgG4 antibody (rozanolixizumab). Route: intravenous or subcutaneous (efgartigimod), intravenous (nipocalimab), subcutaneous (rozanolixizumab). Dosing: cyclic (efgartigimod, rozanolixizumab) vs continuous maintenance (nipocalimab). Rozanolixizumab's niche is the portable, broad-serotype myasthenia option. One caveat matters most: like the others, rozanolixizumab is a prescription biologic administered under medical supervision - not a peptide, not a supplement, and not something to source from a research-chemical vendor. Anything sold as 'rozanolixizumab' or 'UCB7665' outside a pharmacy or clinical trial is unverified and unsafe. This article is educational and is not medical advice. Ready to track your peptide research? [Open PepTracker Pro](https://app.peptrackerpro.com) PepTracker Pro Research Team The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges. ## Citations 1. \[1\] UCB announces U.S. FDA approval of RYSTIGGO (rozanolixizumab-noli) for adults with generalized myasthenia gravis - UCB, June 2023 [Source](https://www.ucb.com/newsroom/press-releases/article/ucb-announces-us-fda-approval-of-rystiggor-rozanolixizumab-noli-for-the-treatment-of-adults-with-generalized-myasthenia-gravis) 2. \[2\] FDA Approves Rozanolixizumab-noli for Generalized Myasthenia Gravis - AJMC [Source](https://www.ajmc.com/view/fda-approves-rozanolixizumab-noli-for-generalized-myasthenia-gravis) 3. \[3\] Safety and efficacy of rozanolixizumab in generalised myasthenia gravis (MycarinG): a phase 3 study - The Lancet Neurology, 2023 [Source](https://www.thelancet.com/journals/laneur/article/PIIS1474-4422\(23\)00077-7/abstract) 4. \[4\] Rozanolixizumab in MuSK-antibody-positive gMG: a MycarinG subgroup analysis [Source](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409299/) 5. \[5\] Rozanolixizumab in CIDP (CIDP01): a phase 2a trial and open-label extension - PubMed [Source](https://pubmed.ncbi.nlm.nih.gov/38729747/) 6. \[6\] Rozanolixizumab (UCB7665): identifiers and mechanism - DrugBank DB14919 [Source](https://go.drugbank.com/drugs/DB14919) **Disclaimer:** This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. [Read full research disclaimer →](/research-disclaimer) ## Related Articles [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/zilucoplan-zilbrysq-macrocyclic-peptide-complement-c5-myasthenia-gravis-june-23-2026) Research & Compounds [ ### Zilucoplan (Zilbrysq): The Self-Injectable Peptide That Blocks Complement in Myasthenia Gravis (June 23, 2026) ](/blog/zilucoplan-zilbrysq-macrocyclic-peptide-complement-c5-myasthenia-gravis-june-23-2026) Zilucoplan is a macrocyclic peptide that switches off the final step of the complement cascade. Unlike the IV antibodies that came before it, patients inject it under the skin once a day. Here is how it works and what the evidence shows. PepTracker Pro Team June 23, 2026 9 min read zilucoplanZilbrysqRA101495 [Read](/blog/zilucoplan-zilbrysq-macrocyclic-peptide-complement-c5-myasthenia-gravis-june-23-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/efgartigimod-vyvgart-argx-113-fcrn-antagonist-igg-recycling-myasthenia-gravis-cidp-seronegative-adapt-seron-july-23-2026) Research & Compounds [ ### Efgartigimod (Vyvgart): The Antibody Fragment That Treats Autoimmune Disease by Deleting Your Own Antibodies (July 23, 2026) ](/blog/efgartigimod-vyvgart-argx-113-fcrn-antagonist-igg-recycling-myasthenia-gravis-cidp-seronegative-adapt-seron-july-23-2026) Most autoimmune drugs suppress the whole immune system. Efgartigimod does something narrower and stranger: it blocks the receptor that recycles your antibodies, so your own pathogenic IgG gets thrown out with the trash. In May 2026 the FDA made it the first and only myasthenia gravis drug approved for every antibody serotype. PepTracker Pro Team July 23, 2026 8 min read efgartigimodefgartigimod alfaARGX-113 [Read](/blog/efgartigimod-vyvgart-argx-113-fcrn-antagonist-igg-recycling-myasthenia-gravis-cidp-seronegative-adapt-seron-july-23-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/nipocalimab-imaavy-m281-fcrn-blocker-aglycosylated-antibody-myasthenia-gravis-sjogrens-hdfn-waiha-vivacity-dahlias-unity-july-24-2026) Research & Compounds [ ### Nipocalimab (Imaavy): The FcRn Blocker That Went Everywhere - From Myasthenia Gravis to the Womb (July 24, 2026) ](/blog/nipocalimab-imaavy-m281-fcrn-blocker-aglycosylated-antibody-myasthenia-gravis-sjogrens-hdfn-waiha-vivacity-dahlias-unity-july-24-2026) A day after efgartigimod, meet the other FcRn blocker. Nipocalimab uses the same trick - stop the receptor that recycles your antibodies - but as a full antibody, dosed continuously, and pushed into places no rival has gone: rheumatology, hematology, and even pregnancy. PepTracker Pro Team July 24, 2026 8 min read nipocalimabnipocalimab-aahuM281 [Read](/blog/nipocalimab-imaavy-m281-fcrn-blocker-aglycosylated-antibody-myasthenia-gravis-sjogrens-hdfn-waiha-vivacity-dahlias-unity-july-24-2026) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.